Pregled bibliografske jedinice broj: 844241
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy // Atherosclerosis. Supplement (Amsterdam), 19 (2015), 1-12 doi:10.1016/S1567-5688(15)30001-5 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 844241 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy
Autori
Aguir, Carlos ; ....Reiner, Željko ; ...Ferrari, Roberto ;
Izvornik
Atherosclerosis. Supplement (Amsterdam) (1567-5688) 19
(2015);
1-12
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
atherogenic dyslipidaemia ; cardiovascular risk ; cholesterol ; combination therapy ; fenofibrate ; statins ; tryglicerides
Sažetak
Patients who have elevated triglyceride levels plus low levels of HDL-c are most likely to achieve clinical benefit from fenofibrate - statin combination therapy. In these patients with AD, achieving target non-HDL-c levels should be a key focus of CV risk management, and the use of non- HDL-c was advocated to provide a better measure of CV risk than LDL-c levels.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
108-1080134-0121 - Percepcija i prevencija čimbenika rizika za aterosklerozu u Hrvatskoj (Reiner, Željko, MZOS ) ( CroRIS)
Ustanove:
Klinički bolnički centar Zagreb
Profili:
Željko Reiner
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
